Therapeutic Perspectives of IL1 Family Members in Liver Diseases:An Update  

作　　者：Ines Bilić Ćurčić Tomislav Kizivat Ana Petrović Robert Smolić Ashraf Tabll George Y.Wu Martina Smolić 

机构地区：[1]Faculty of Medicine Osijek,University of Osijek,Osijek,Croatia [2]University Hospital Osijek,Osijek,Croatia [3]Faculty of Den-tal Medicine and Health Osijek,University of Osijek,Osijek,Croatia [4]National Research Center,Giza,Egypt [5]Egypt Center for Research and Regenerative Medicine(ECRRM),Cairo,Egypt [6]University of Connecticut Health Center,Farmington,CT,USA

出　　处：《Journal of Clinical and Translational Hepatology》2022年第6期1186-1193,共8页临床与转化肝病杂志（英文版）

基　　金：Croatian Ministry of Science and Education dedicated to multi-institutional fund-ing of scientific activity at the J.J.Strossmayer University of Osijek,Osijek,Croatia,grant number ZUP2018-90(to Ines Bilić Ćurčić).

摘　　要：Interleukin(IL)1 superfamily members are a cornerstone of a variety of inflammatory processes occurring in various organs including the liver.Progression of acute and chronic liver diseases regardless of etiology depends on the stage of hepatocyte damage,the release of inflammatory cytokines and disturbances in gut microbiota.IL1 cytokines and re-ceptors can have pro-or anti-inflammatory roles,even dual functionalities conditioned by the microenvironment.Devel-oping novel therapeutic strategies to block the IL1/IL1R sign-aling pathways seems like a reasonable option.This mode of action is now exploited by anakinra and canakinumab,which are used to treat different inflammatory illnesses,and studies in liver diseases are on the way.In this mini review,we have focused on the IL1 superfamily members,given their cru-cial role in liver inflammation diseases,specifically discussing their potential role in developing new treatment strategies.

关 键 词：Interleukin 1 superfamily members INFLAMMATION Acute liver dis-ease Chronic liver disease Therapy 

分 类 号：R575[医药卫生—消化系统]